Hansoh Pharmaceutical Group Co Limited/ADR
No SEC Form 4 filings for $HNSPF in the last 30 days.
See all $HNSPF insider activity →Hansoh Pharma (HNSPF) and Roche (RHHBY) agreed to collaborate on cancer drugs, with a deal potentially worth over $14B. The partnership focuses on antibody-drug conjugates. Financial terms include upfront, milestone, and royalty payments to Hansoh.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning HNSPF (Hansoh Pharmaceutical Group Co Limited/ADR). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Positive catalyst from a major global partnership.
AlphAI scores every news story that mentions HNSPF with an AI model for sentiment and relevance, and aggregates insider trades from Hansoh Pharmaceutical Group Co Limited/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Hansoh Pharma (HNSPF) and Roche (RHHBY) agreed to collaborate on cancer drugs, with a deal potentially worth over $14B. The partnership focuses on antibody-drug conjugates. Financial terms include upfront, milestone, and royalty payments to Hansoh.
2 min read